[
    [
        {
            "time": "",
            "original_text": "4+7带量采购价格战打响？恒瑞医药主动降价",
            "features": {
                "keywords": [
                    "4+7",
                    "带量采购",
                    "价格战",
                    "恒瑞医药",
                    "降价"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "4+7带量采购价格战打响？恒瑞医药主动降价",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "陆股通周报:北上资金减持大消费",
            "features": {
                "keywords": [
                    "陆股通",
                    "北上资金",
                    "减持",
                    "大消费"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "陆股通周报:北上资金减持大消费",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "从美国仿制药企业兴衰看中外药企的估值差异和竞争策略:崛起和失落",
            "features": {
                "keywords": [
                    "仿制药",
                    "估值差异",
                    "竞争策略",
                    "中美药企"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "从美国仿制药企业兴衰看中外药企的估值差异和竞争策略:崛起和失落",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "理成资产CEO吴圣涛：价值投资者的黄金时段",
            "features": {
                "keywords": [
                    "理成资产",
                    "吴圣涛",
                    "价值投资",
                    "黄金时段"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "理成资产CEO吴圣涛：价值投资者的黄金时段",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "235亿资金争夺20股：主力资金重点出击9股(名单)",
            "features": {
                "keywords": [
                    "资金争夺",
                    "主力资金",
                    "重点出击",
                    "个股名单"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "235亿资金争夺20股：主力资金重点出击9股(名单)",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "今日两市超大账户减持的50只个股",
            "features": {
                "keywords": [
                    "两市",
                    "超大账户",
                    "减持",
                    "个股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "今日两市超大账户减持的50只个股",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：国家医保局开展DRGS国家试点申报工作推进医保支付方式改革",
            "features": {
                "keywords": [
                    "医疗保健",
                    "国家医保局",
                    "DRGS",
                    "医保支付改革"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：国家医保局开展DRGS国家试点申报工作推进医保支付方式改革",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "看好中国｜健康中国——部分医药股仍具备中期投资价值",
            "features": {
                "keywords": [
                    "健康中国",
                    "医药股",
                    "中期投资价值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "看好中国｜健康中国——部分医药股仍具备中期投资价值",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药：PD1单抗与阿帕替尼联合用药开展国际多中心临床",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PD1单抗",
                    "阿帕替尼",
                    "联合用药",
                    "国际多中心临床"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：PD1单抗与阿帕替尼联合用药开展国际多中心临床",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "中国医药出海新突破 国产胰岛素类似物首次输出欧美",
            "features": {
                "keywords": [
                    "中国医药",
                    "出海",
                    "胰岛素类似物",
                    "欧美市场"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中国医药出海新突破 国产胰岛素类似物首次输出欧美",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "2018年A股牛股基因揭秘 229只逆势飘红股有三大特征",
            "features": {
                "keywords": [
                    "A股",
                    "牛股",
                    "基因揭秘",
                    "逆势飘红",
                    "特征"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2018年A股牛股基因揭秘 229只逆势飘红股有三大特征",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药:“SHR~1210+阿帕替尼”1b期数据优异，三期临床结果可期",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR~1210",
                    "阿帕替尼",
                    "1b期数据",
                    "三期临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药:“SHR~1210+阿帕替尼”1b期数据优异，三期临床结果可期",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]